. 2012 Dec;28(12):1766–1774. doi: 10.1089/aid.2011.0383

Table 1.

Clinical, Immunologic, and Virologic Characteristics

Patient characteristics			Virologic analyses of variants
Date	ART	CD4 cell count, cells/mm³	Site of origin^a	HIV-1 RNA load, log copies/ml	Total variants, N	Recombinants, N, (%)
5-98	None	120	Plasma	5.34	NA	NA
2-00	AZT, 3TC, NVP	359	Plasma	4.30	22	Parental strains^b
			CVL	4.85	33	Parental strains^b
7-00	AZT, 3TC, NVP	387	Plasma	4.30	17	1(6)
			CVL	4.15	17	5 (29)
2-01	AZT, 3TC, NVP	368	Plasma	3.68	9	2(22)
7-01	AZT, 3TC, NVP	358	Plasma	3.99	7	4 (57)
2-02	AZT, 3TC, NVP	530	Plasma	3.76	10	2 (20)
7-02	None	224	Plasma	4.77	10	3 (30)
1-03	AZT, 3TC, NVP	338	Plasma	4.18	9	3 (33)
6-03	None	211	Plasma	5.80	11	1 (9)
12-03	AZT, 3TC, NVP	249	Plasma	3.20	14	2 (14)
Total					159	23 (22)^c

^{^a}

Sequences were obtained from plasma at each time point and from CVL obtained in February and July of 2000. At later time points, CVL viral loads were <80 copies/ml. Data in the three columns furthest to the right refer to analyses of samples from either CVL or plasma.

^{^b}

ART was initiated shortly before the 2-00 visit and resistance mutations were detected for the first time in samples from that visit. We therefore considered variants from that time point as putative parental strains in the recombination analyses.

^{^c}

Because strains obtained in 2-00 were considered as putative parental strains, the 104 variants obtained after 2-00 were included to calculate the percentage of recombinant variants.

ART, antiretroviral therapy; AZT, zidovudine; 3TC, lamivudine; NVP, nevirapine; CVL, cervicovaginal lavage; NA, not analyzed because the consensus sequence was obtained only for this time point.